Survival and regional disease control after isolation-perfusion for invasive stage I melanoma of the extremities
- PMID: 1247954
- DOI: 10.1002/1097-0142(197601)37:1<188::aid-cncr2820370127>3.0.co;2-s
Survival and regional disease control after isolation-perfusion for invasive stage I melanoma of the extremities
Abstract
Excision of the primary and isolation-perfusion with 1-phenylalanine mustard was the treatment in 199 patients with invasive Stage I melanoma of the extremities with the goal of improving regional disease control and long-term survival. The determinant survival in patients followed 5-15 years was 83%; Berkson-Gage survivals were 98% at 2 years, 88% at 5 years, and 84% at 10 years. The site of first recurrence was determined in all 49 (25%) patients who failed treatment: three (2%) developed local recurrence, six (3%) developed intransit recurrence, 24 (13%) developed positive regional lymph nodes, 15 (8%) developed systemic metastases, and one developed local recurrence plus positive regional nodes. Of these 49 patients failing treatment, 15 (31%) are currently surviving with no evidence of disease after retreatment of the recurrence. These data are compared to historical controls in the literature. It is concluded that regional control rates are improved by perfusion and that survival has probably been improved. In 14 patients treated by perfusion without local excision, regional control and survival was poor. Single drug (L-PAM) perfusion with the techniques employed is effective in controlling regional subclinical disease, but the primary should be widely excised.
Similar articles
-
Prophylactic isolation-perfusion as the primary therapy for invasive malignant melanoma of the limbs.Ann Surg. 1975 Sep;182(3):316-24. doi: 10.1097/00000658-197509000-00014. Ann Surg. 1975. PMID: 1164059 Free PMC article.
-
Regional chemotherapy for melanoma. A 35-year experience.Ann Surg. 1994 Oct;220(4):520-34; discussion 534-5. doi: 10.1097/00000658-199410000-00010. Ann Surg. 1994. PMID: 7944662 Free PMC article.
-
Effect of variation of drug dosage on disease control and regional toxicity in prophylactic perfusion for Stage I extremity melanoma.J Surg Oncol. 1984 Dec;27(4):215-8. doi: 10.1002/jso.2930270402. J Surg Oncol. 1984. PMID: 6503295
-
Isolated limb perfusion for melanoma.J Surg Oncol. 2002 Apr;79(4):252-5. doi: 10.1002/jso.10077. J Surg Oncol. 2002. PMID: 11920783 Review. No abstract available.
-
Surgical issues in the management of melanoma.Curr Opin Oncol. 1997 Mar;9(2):183-8. doi: 10.1097/00001622-199703000-00014. Curr Opin Oncol. 1997. PMID: 9161799 Review.
Cited by
-
Functional morbidity of hyperthermic isolated regional perfusion of the extremities.Ann Surg Oncol. 1994 Sep;1(5):382-8. doi: 10.1007/BF02303810. Ann Surg Oncol. 1994. PMID: 7850539 Clinical Trial.
-
Isolated regional perfusion in malignant melanoma of the extremities.World J Surg. 1987 Aug;11(4):527-33. doi: 10.1007/BF01655819. World J Surg. 1987. PMID: 3630197 No abstract available.
-
Isolation-perfusion of the liver with 5-fluorouracil.Ann Surg. 1985 Mar;201(3):337-43. doi: 10.1097/00000658-198503000-00014. Ann Surg. 1985. PMID: 3977437 Free PMC article.
-
Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding.Ann Surg. 1988 Jul;208(1):36-41. doi: 10.1097/00000658-198807000-00005. Ann Surg. 1988. PMID: 3133994 Free PMC article.
-
Hyperthermic perfusion with chemotherapy for melanoma of the extremities.World J Surg. 1989 Sep-Oct;13(5):598-602. doi: 10.1007/BF01658878. World J Surg. 1989. PMID: 2815804 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Miscellaneous